A market projected to reach $156 billion by 2035 at a 21.5% annual clip does not wait for a company to finish finding itself, which is precisely why Kromatid’s board moved quickly to install a permanent CEO after an extended interim stretch. Matthew Hemstreet, who joined Kromatid as VP of Global Marketing in 2024 and has launched more than 30 products across companies including Medtronic and Terumo Blood and Cell Technologies, steps into the chief executive role with a mandate to turn a platform business into what the company explicitly frames as an industry standard for genomic integrity assessment.
The timing is not accidental. In April 2026, the FDA issued draft guidance on safety assessment of genome editing in gene therapy products, directing developers toward rigorous nonclinical studies using next-generation sequencing and bioinformatics to evaluate off-target editing and loss of genome integrity. That guidance is a direct commercial catalyst for a company selling chromosomal analysis tools to cell and gene therapy developers. The KROMASURE platform, built on what Kromatid describes as proprietary imaging combined with a library of millions of chromosome images, sits at exactly the intersection the FDA is now formalizing. Hemstreet’s priority is accelerating adoption of that platform while the regulatory window is open and developer demand is acute.
The strategic transformation Hemstreet inherits reflects a company that has been sharpening its positioning rather than simply growing headcount. Interim CEO Terry Opgenorth, who stays on as a board member, refocused the brand around structural genomic integrity and single-cell analytics, expanded the analysis portfolio, and built out what Kromatid calls a genomic intelligence platform. That groundwork, combined with an $8 million Series C closed in 2025 led by BroadOak Capital Partners, gives Hemstreet real capital and a cleaner commercial story to take to pharma sponsors, CDMOs, and academic research institutions simultaneously.
The single metric worth tracking here is KROMASURE platform adoption within CDMO partnerships. CDMOs sit upstream of every cell therapy program they manufacture, and embedding genomic integrity assessment as a default quality step at that layer is the fastest path to the industry-standard status Kromatid is explicitly targeting. If Hemstreet closes two or three marquee CDMO agreements in the next 12 months, the platform argument becomes self-reinforcing.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
